Kronos Bio, Inc. (KRON)
NASDAQ: KRON · Real-Time Price · USD
0.903
+0.029 (3.28%)
Nov 22, 2024, 4:00 PM EST - Market closed
Company Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States.
Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.
The company was incorporated in 2017 and is headquartered in San Mateo, California.
Kronos Bio, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Oct 9, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Norbert Bischofberger |
Contact Details
Address: 1300 South El Camino Real, Suite 400 San Mateo, California 94402 United States | |
| Phone | (650) 781-5200 |
| Website | kronosbio.com |
Stock Details
| Ticker Symbol | KRON |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001741830 |
| CUSIP Number | 50107A104 |
| ISIN Number | US50107A1043 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Norbert W. Bischofberger Ph.D. | President, Chief Executive Officer and Director |
| Joshua A. Kazam | Co-Founder and Director |
| David M. Tanen J.D. | Secretary and Director |
| Dr. Deborah A. Knobelman Ph.D. | Chief Operating Officer and Chief Financial Officer |
| Dr. Charles Lin Ph.D. | Chief Scientific Officer |
| Allison Frisbee J.D. | Chief Administrative Officer |
| Dr. Margaux Bennett Ph.D. | Vice President of Corporate Development and Investor Relations |
| Dr. Elizabeth A. Olek D.O., M.P.H. | Senior Vice President of Clinical Development |
| Wes Trotter Ph.D. | Senior Vice President of Drug Discovery and Pharmaceutical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | EFFECT | Notice of Effectiveness |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 7, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 8, 2024 | 8-K | Current Report |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Jul 2, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jun 27, 2024 | 8-K | Current Report |